Home > PE Ratio > GLAND PHARMA

GLAND PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of GLAND PHARMA is 43.22.

Share Price ₹1,813.8Dec 03,2024
Market Cap ₹29,890.6 Cr
Earnings-TTM₹691.6 CrTTM-Consolidated Results
Price/Earnings43.22xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Top Undervalued Mid Cap Stocks
Best 1M Momentum Mid Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of GLAND PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of GLAND PHARMA is calculated as :

Current Market Cap [ ₹29,890.6 Cr] as on Dec 03,2024

(/) Earnings [ ₹691.6 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 43.22x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for GLAND PHARMA , the investors are currently willing to pay 43.22 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLAND PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of GLAND PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of GLAND PHARMA


PE Ratio Performance Analysis for GLAND PHARMA

- GLAND PHARMA 's latest p/e ratio is 43.22x.

- GLAND PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 30.20x.

- GLAND PHARMA 's operated at median p/e ratio of 39.27x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, GLAND PHARMA 's p/e ratio peaked in Mar2022 at 44.33x.

- GLAND PHARMA 's p/e ratio hit its five-year low in Mar2020 of 0x.


How does GLAND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
GLAND PHARMA 691.5743.2229,890.6
SUN PHARMACEUTICAL INDUSTRIES LTD11,136.5038.75431,544.0
CIPLA LTD4,485.2227.63123,920.0
DR REDDYS LABORATORIES LTD5,406.8018.91102,224.0
ZYDUS LIFESCIENCES LTD4,298.9022.9998,832.3
DIVIS LABORATORIES LTD1,836.0089.80164,865.0
MANKIND PHARMA LTD2,124.8648.25102,527.0
TORRENT PHARMACEUTICALS LTD1,802.0063.14113,772.0
LUPIN LTD2,651.9435.8194,953.0
AUROBINDO PHARMA LTD3,598.8320.4473,544.0
ABBOTT INDIA LTD1,284.6647.0560,440.8

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLAND PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 18.91x
Max industry PE 89.80x
Median industry PE 38.75x
Average industry PE 41.45x



You may also like the below Video Courses